Psoriasis treatment: current and emerging directed therapies - PubMed (original) (raw)
Review
. 2005 Mar;64 Suppl 2(Suppl 2):ii87-90; discussion ii91-2.
doi: 10.1136/ard.2004.032276.
Affiliations
- PMID: 15708946
- PMCID: PMC1766866
- DOI: 10.1136/ard.2004.032276
Review
Psoriasis treatment: current and emerging directed therapies
L S Winterfield et al. Ann Rheum Dis. 2005 Mar.
Abstract
Quality of life studies in patients with cutaneous psoriasis attest to its significant impact on day to day activities and personal social interactions. Up to 40% of patients with psoriasis may develop psoriatic arthritis, usually within 5-10 years after onset of the cutaneous disease, heightening quality of life issues. These data have prompted an increased awareness and interest in more aggressive management of psoriasis; coupled with a better understanding of immunopathogenesis, this has led to the development of new agents targeting specific cells and molecules involved in the development and maintenance of psoriatic plaques. Although non-biological therapies, including methotrexate and ciclosporin, show significant efficacy their side effect profiles have precluded their long term use for moderate to severe psoriasis. This review concentrates on new biological agents, focusing on the three agents approved for psoriasis within the past 18 months (alefacept, efalizumab, and etanercept). Phase II and III trial data on other agents in development (adalimumab and infliximab) are also presented. Surveys show many patients want to be treated more aggressively. It is hoped that the introduction of new agents that are more targeted and that hold the promise of fewer side effects will cause patients and their physicians to reconsider systemic treatment and, as a consequence, stimulate other patients to reconsider treatment for psoriasis. Close cooperation between dermatologists and rheumatologists, particularly in the area of psoriatic joint disease, will enhance these considerations.
Similar articles
- TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
Wcisło-Dziadecka D, Zbiciak-Nylec M, Brzezińska-Wcisło L, Mazurek U. Wcisło-Dziadecka D, et al. Postgrad Med J. 2016 Mar;92(1085):172-8. doi: 10.1136/postgradmedj-2015-133419. Epub 2015 Dec 30. Postgrad Med J. 2016. PMID: 26719452 Review. - Treatment of psoriasis and psoriatic arthritis.
Papoutsaki M, Costanzo A. Papoutsaki M, et al. BioDrugs. 2013 Jan;27 Suppl 1:3-12. doi: 10.1007/BF03325637. BioDrugs. 2013. PMID: 23990277 Review. - Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A. Papoutsaki M, et al. BioDrugs. 2013 Jan;27 Suppl 1:13-23. doi: 10.1007/BF03325638. BioDrugs. 2013. PMID: 23990278 Review. - Combination therapy of biologics with traditional agents in psoriasis.
Guenther LC. Guenther LC. Skin Therapy Lett. 2011 Jun;16(6):1-3. Skin Therapy Lett. 2011. PMID: 21833461 - Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, Langley RG, Paul CF, Puig L, Lebwohl MG. van de Kerkhof PC, et al. J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2002-10. doi: 10.1111/jdv.13150. Epub 2015 Apr 16. J Eur Acad Dermatol Venereol. 2015. PMID: 25885420 Free PMC article.
Cited by
- Erythema Dyschromicum Perstans After Adalimumab Treatment.
Alsisi GG, Alsisi MH, Alhowaish AK, Alshammari WS. Alsisi GG, et al. Cureus. 2022 Dec 6;14(12):e32264. doi: 10.7759/cureus.32264. eCollection 2022 Dec. Cureus. 2022. PMID: 36620779 Free PMC article. - Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report.
Ahn H, Lee SY, Jung WJ, Pi J, Lee KH. Ahn H, et al. World J Clin Cases. 2021 Aug 16;9(23):6798-6803. doi: 10.12998/wjcc.v9.i23.6798. World J Clin Cases. 2021. PMID: 34447827 Free PMC article. - Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis.
Light JG, Su JJ, Feldman SR. Light JG, et al. Clin Cosmet Investig Dermatol. 2021 Jan 15;14:55-63. doi: 10.2147/CCID.S235242. eCollection 2021. Clin Cosmet Investig Dermatol. 2021. PMID: 33488109 Free PMC article. Review. - Weighted gene coexpression network and experimental analyses identify lncRNA SPRR2C as a regulator of the IL-22-stimulated HaCaT cell phenotype through the miR-330/STAT1/S100A7 axis.
Luo M, Huang P, Pan Y, Zhu Z, Zhou R, Yang Z, Wang C. Luo M, et al. Cell Death Dis. 2021 Jan 15;12(1):86. doi: 10.1038/s41419-020-03305-z. Cell Death Dis. 2021. PMID: 33452236 Free PMC article. - Diterpenoids and Triterpenoids From Frankincense Are Excellent Anti-psoriatic Agents: An in silico Approach.
Halim SA, Khan A, Csuk R, Al-Rawahi A, Al-Harrasi A. Halim SA, et al. Front Chem. 2020 Jun 25;8:486. doi: 10.3389/fchem.2020.00486. eCollection 2020. Front Chem. 2020. PMID: 32671018 Free PMC article.
References
- J Am Acad Dermatol. 1991 Apr;24(4):591-4 - PubMed
- J Am Acad Dermatol. 2001 Oct;45(4):544-53 - PubMed
- N Engl J Med. 1979 Sep 6;301(10):555 - PubMed
- J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):315-21 - PubMed
- Arch Dermatol Res. 1983;275(3):181-9 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous